Whalesbook
From Daily Pills to a Single Infusion
The field of heart disease treatment may be shifting from daily medications and regular injections to permanent genetic changes. Eli Lilly presented new data on VERVE-102 at the European Atherosclerosis Society congress, suggesting this transition is becoming possible. The therapy uses a base editor to reduce the activity of the PCSK9 gene, which is a major factor in high LDL cholesterol. The goal is to provide a "one-and-done" treatment for people with certain genetic high cholesterol conditions and early heart disease.
Promising Data and Company Integration
Unlike standard cholesterol drugs that require patients to take them consistently, VERVE-102 uses tiny fat-based particles to deliver its genetic material directly to the liver. The highest dose achieved a 62% drop in LDL cholesterol, a result that is competitive with existing PCSK9 drugs like Amgen's Repatha. Eli Lilly acquired Verve Therapeutics, the developer of VERVE-102, for up to $1.3 billion, strengthening its position in genetic medicine. The company is using its significant financial strength, with a market cap around $1 trillion, to invest in promising early-stage biotech projects.
Risks of Permanent DNA Changes
While the idea of permanently lowering cholesterol is appealing, it also carries long-term risks. Because base editing permanently changes a person's DNA, scientists are cautious about potential unintended changes to the genome. Past related therapies faced issues with inflammation from the delivery method. Early trials also lacked a long-term comparison group, making it hard to rule out the treatment as a cause for any rare heart events. Any signs of unintended DNA changes or liver problems in larger studies could lead to strict regulatory review and potentially halt the trial.
What Comes Next for VERVE-102
Eli Lilly plans to begin Phase 2 studies for VERVE-102 by the end of 2026. The effectiveness shown so far is positive, but the therapy's success will depend on its long-term safety and whether it offers a clear cost advantage over current treatments. Eli Lilly is also developing other heart-related therapies, including VERVE-201, which targets a different gene. This shows a broad strategy to lead the market in new cardiovascular and metabolic treatments.